Promotive Communications

Lab Focus FebMarch digital

Laboratory Focus is Canada's leading editorial-based lab publication. Providing readers with the latest technology updates through application and tech notes, as well as covering new products and trends in laboratories across Canada.

Issue link: http://laboratoryfocus.uberflip.com/i/479401

Contents of this Issue

Navigation

Page 0 of 20

R&D News ......................... 1 Pharma Notes .................... 5 Appointments .................... 6 New Products .................. 15 Calendar .......................... 17 App Reviews ..................... 18 P h a r m a c e u t i c a l c l i n i c a l c h e m i c a l f o o d e n v i r o n m e n t w w w . l a b o r a t o r y f o c u s . c a february/march 2015 volume 19, number 1 Publications Mail Registration Number: 40052410 merck joins structural Genomics consortium (sGc) makes $7.5 million contribution tario and around the world, use of the probes will expand the un- derstanding of biology in multiple disease areas, particularly cancer and inflammatory diseases. According to Merck Canada Inc. president and managing director Chirfi Guindo, the SGC's track record for delivering high-quality science, along with Toronto's eco- system of world-class hospitals and research labs as well as a strong commitment of collaboration be- tween government and industry, make the SGC an ideal research partner. "At Merck, we strive to identify and support research areas that will have the most impact on ful- filling the unmet medical needs of patients, who are at the core of everything we do," he said. "In Canada, Merck is very pleased to be able to encourage innovation and research across an established SGC collaborative network of more than 250 academic laboratories at leading institutions." Developing an "open source" public-private partnership The SGC is creating an "open source" public-private partner- ship that generates knowledge, technologies, and research tools to discover and characterize "pio- neer" drug discovery targets. The partnership will leverage past and future investments made into the SGC by its public and private sector funders, and its large network of collaborators based at leading aca- demic institutions worldwide. The overarching aim of the partnership is to enable private sector funders to advance a significant number of pioneer targets into proprietary drug discovery programs. "At the heart of our partnership is a commitment to transparency and quality," said Dr. Aled Edwards, founding and current CEO of the Structural Genomics Consortium (SGC). The SGC is funded by Abbvie, Bayer, Boehringer Ingelheim, the Canada Foundation for Innovation, Eli Lilly Canada, Genome Canada, GlaxoSmithKline, Janssen, Merck Canada, Novartis, the Ontario Ministry of Research & Innovation, Pfizer, Takeda, and the Wellcome Trust. To see this story online visit http://www.laboratoryfocus. ca/?p=2841 The Structural Genomics Consor- tium (SCC) Toronto announces it has added global pharma giant Merck as its newest member . In addition to joining the consor- tium as a partner, Merck is contrib- uting $7.5 million to the network. The money will go towards sup- porting projects with a focus on pre-competitive research. One of the projects will see the partners developing small inhibitory mol- ecules called chemical probes to study epigenetic mechanisms of regulation. In collaboration with leading clinical institutions in On- tips, tricks and information for the ergonomic design of your laboratory Page 7 exploiting macrocycle space for drug discovery Page 10 (From left to right) Dr. Ronan O'Hagan, Dr. Aled Edwards, The Honourable Reza Moridi, Mr. Chirfi Guindo and Ms. Jennifer Chan. (CNW Group/Merck)

Articles in this issue

Links on this page

view archives of Promotive Communications - Lab Focus FebMarch digital